Abstract:BACKGROUND: Analysis of genomic alterations in circulating tumor DNA is gaining traction in clinical oncology and can provide insights into tumor biology without the need for invasive tissue sampling. In addition to genetic alterations, epigenomic reprogramming leads to transcriptional dysregulation and drives cancer phenotypes including molecular subtypes, histologic subtypes, and mechanisms resistance. As current liquid biopsy assays fail to effectively capture transcriptional biology, new approaches are needed to examine the transcriptional status of therapeutic gene targets and pathways including those relevant to rapidly emerging classes such as antibody-drug conjugates (ADC) and radio-conjugates. METHODS: We developed a novel multimodal assay that reveals genome-wide transcriptional activity of promoters, enhancers from chromatin and surveys the DNA methylome using 1ml of patient plasma. We applied this assay to patient plasma samples from across 15 tumor types generating 7000 genome-wide transcriptional profiles. RESULTS: We confirmed a significant correlation between epigenomic signals of transcriptional activation and gene expression from RNA-seq (Promoter vs RNA-seq: ⍴ =0.95, p<0.05; DNA methylation vs RNA-seq: ⍴=-0.16, p<0.05). We identified transcriptional activation in cancer patient plasma of well-established cancer-associated biomarkers (e.g. MET, DLL3, PSMA) in a tumor-specific manner. Epigenomic profiling simultaneously inferred the expression of multiple pertinent ADC targets currently under investigation (MET, HER2, HER3, TROP2, B7H4 in breast cancer), and SLFN11, a known biomarker for sensitivity to these agents. Unlike targeted panels, the platform assesses transcriptional regulation genome-wide, enabling the assessment of transcriptional activity of select genes as well as related pathways. For example, a multimodal classifier robustly predicted HER2 status across metastatic breast cancer plasma samples based on features both within the HER2 amplicon as well as HER2-distal genes that are activated in HER2+ cancers (AUC = 0.93, 0.84-1.0 95% CI). The multimodal classifier out-performed individual analyte-based classifiers (AUCPromoter+Enhancer = 0.85, 0.72-0.98 95% CI; AUCDNA-methylation = 0.69, 0.48-0.90 95% CI). Epigenomic signatures were also used to delineate multiple mechanisms of resistance to androgen receptor signaling inhibition in prostate cancer, including reactivation of the androgen receptor, glucocorticoid signaling bypass, and histological transformation to a neuroendocrine subtype. CONCLUSION: This comprehensive epigenomic liquid biopsy assay provides a platform for simultaneous genome-wide transcriptional assessment of disease and therapy relevant genes and pathways, representing a paradigm shift in our ability to longitudinally monitor cancer in individual patients. Citation Format: Travis Clark, Ji-Heui Seo, Anthony D'Ippolito, Aparna Gorthi, Jonathan Beagan, Jamey Guess, Amy Donahue, Mandy Greene, Alyssa Lau, Fernando Ramirez, Kristian Cibulskis, Hyun-Hwan Jeong, Matthew Davidsohn, Gitanjali Lakshminarayanam, Michael Coyne, Baovy Tran, Tyrone Tamakloe, Hathairat Sawaengsri, Marc Eid, Karl Semaan, Brad Fortunato, Corrie A. Painter, Juliann Chmielecki, Toni K. Choueiri, J Carl Barrett, Geoff Otto, Matthew L. Freedman, Matthew L. Eaton, Sylvan C. Baca. Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 963.

Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics

Liquid biopsy epigenomic profiling for cancer subtyping

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Abstract 963: Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer

Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Chromatin and Nucleosome-Associated Features in Liquid Biopsy: Implications for Cancer Biomarker Discovery

Development of a Plasma Cell-Free DNA Chromosome Instabilities Assay for Early Cancer Detection and Treatment Response Monitoring of Multiple Tumor Types.

Sensitive detection of pancreatic adenocarcinoma using plasma cell-free DNA methylomes.

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment

Analysis of a Cell-Free DNA-based Cancer Screening Cohort Links Fragmentomic Profiles, Nuclease Levels, and Plasma DNA Concentrations

Inferring gene expression from cell-free DNA fragmentation profiles

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

Detection of rare mutations, copy number alterations, and methylation in the same template DNA molecules

Dissecting the nuances of cancer epigenomics in liquid biopsy

Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling

Noninvasive Cancer Detection by Extracting and Integrating Multi-Modal Data from Whole-Methylome Sequencing of Plasma Cell-Free DNA

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling.